Compare Amphastar Pharmaceuticals Inc (AMPH) vs ProShares UltraPro S&P500 (UPRO) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

UPRO trades at $146.15, up 1.21% with a bullish technical outlook from moving averages. The stock shows neutral oscillator signals with RSI at 53.33 suggesting balanced momentum. Recent news highlights S&P 500 momentum driven by AI infrastructure spending and strong earnings expectations, though Fed policy and geopolitical risks create volatility. The dividend of $0.30 is scheduled for June 2026.

The stock benefits from AI-driven market tailwinds but faces valuation concerns and sector rotation risks. Earnings growth remains the key catalyst, though stretched valuations and Fed tightening pose headwinds. Institutional sentiment appears cautiously optimistic given the technical strength and sector momentum.